ACC/AHA guideline on the secondary prevention of hypercholestrolemia: Difference between revisions
< ACC
Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Hypercholesterolemia}} {{CMG}} ==Overview== ==Initiating statin therapy in individuals with clinical ASCVD== Image:ACCAHA cholesterol treatment ASCVD.jpg|800px...") |
m (Mmir moved page ACC AHA Guideline on the secondary prevention of hypercholestrolemia to ACC/AHA guideline on the secondary prevention of hypercholestrolemia) |
||
| (8 intermediate revisions by 4 users not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
== | ===2013 ACC AHA guideline on the treatment of blood cholesterol secondary prevention=== | ||
===Secondary Prevention=== | |||
{|class="wikitable" width="80%" | |||
|- | |||
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]] | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1. '''High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''2. '''In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|Level of Evidence: A]])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
== | {|class="wikitable" width="80%" | ||
|- | |||
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]] | |||
|- | |||
| bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1. '''In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it.''([[ACC AHA guidelines classification scheme#Classification of Recommendations|''Level of Evidence: C'']])''<nowiki>"</nowiki> | |||
|- | |||
|} | |||
===Initiating and Management of Statin Therapy in Individuals with Clinical ASCVD=== | |||
[[Image:ACCAHA cholesterol treatment ASCVD.jpg|800px]] | [[Image:ACCAHA cholesterol treatment ASCVD.jpg|800px]] | ||
<font size="-3">''Clinical ASCVD is defined as acute coronary syndromes or history of MI, stable or unstable angina, coronary revascularization, stroke, or TIA presumed to be of atherosclerotic origin, and peripheral arterial disease or revascularization.''</font> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WikiDoc Help Menu}} | |||
{{WikiDoc Sources}} | |||
[[Category:Disease]] | [[Category:Disease]] | ||
| Line 15: | Line 39: | ||
[[Category:Up-To-Date]] | [[Category:Up-To-Date]] | ||
[[Category:Up-To-Date cardiology]] | [[Category:Up-To-Date cardiology]] | ||
Latest revision as of 14:34, 27 February 2018
Template:Hypercholesterolemia Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
2013 ACC AHA guideline on the treatment of blood cholesterol secondary prevention
Secondary Prevention
| Class I |
| "1. High-intensity statin therapy should be initiated or continued as first-line therapy in women and men ≤75 years of age who have clinical ASCVD, unless contraindicated.(Level of Evidence: A)" |
| "2. In individuals with clinical ASCVD* in whom high-intensity statin therapy would otherwise be used, when high-intensity statin therapy is contraindicated† or when characteristics predisposing to statin-associated adverse effects are present, moderate-intensity statin should be used as the second option if tolerated.(Level of Evidence: A)" |
| Class IIa |
| "1. In individuals with clinical ASCVD >75 years of age, it is reasonable to evaluate the potential for ASCVD risk-reduction benefits and for adverse effects, drug-drug interactions and to consider patient preferences, when initiating a moderate- or high-intensity statin. It is reasonable to continue statin therapy in those who are tolerating it.(Level of Evidence: C)" |
Initiating and Management of Statin Therapy in Individuals with Clinical ASCVD
Clinical ASCVD is defined as acute coronary syndromes or history of MI, stable or unstable angina, coronary revascularization, stroke, or TIA presumed to be of atherosclerotic origin, and peripheral arterial disease or revascularization.